Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...